重大事件
即時報告
8-K
2026-06-03
Cocrystal Pharma提交8-K報告 披露業務發展最新動向
AI 繁中摘要
Cocrystal Pharma提交8-K表格披露最新業務發展動向
美國生物製藥公司Cocrystal Pharma, Inc.（納斯達克代碼：COCP）於2026年6月3日向SEC提交了一份8-K當前報告，涵蓋Item 7.01
展開英文正文
EDGAR Filing Documents for 0001493152-26-026965 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001493152-26-026965 Filing Date 2026-06-03 Accepted 2026-06-03 07:00:17 Documents 13 Period of Report 2026-06-03 Items Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K form8-k.htm iXBRL 8-K 38674 2 EX-99.1 ex99-1.htm EX-99.1 20229 3 GRAPHIC ex99-1_001.jpg GRAPHIC 12987 Complete submission text file 0001493152-26-026965.txt 245668 Data Files Seq Description Document Type Size 4 XBRL SCHEMA FILE cocp-20260603.xsd EX-101.SCH 3035 5 XBRL LABEL FILE cocp-20260603_lab.xml EX-101.LAB 34239 6 XBRL PRESENTATION FILE cocp-20260603_pre.xml EX-101.PRE 22372 16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3114 Mailing Address 19805 N. CREEK PARKWAY BOTHELL WA 98011 Business Address 19805 N. CREEK PARKWAY BOTHELL WA 98011 (786) 459-1831 Cocrystal Pharma, Inc. (Filer) CIK: 0001412486 (see all company filings) EIN.: 352528215 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38418 | Film No.: 261058896 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)